Markets
Where is Phylloceuticals focused?
Phylloceuticals is currently focused on several regions around the globe including Australia, Vietnam, Singapore, China, Africa, and the MENA region.
- Global biologics production does not have the capacity to supply many of these regions without large investment and the capital cost of traditional production systems is very high
- Supplying medications, rapidly and cost effectively, is difficult
- Developing regions are seeking to develop local facilities to solve local problems
- Plant-made pharma offers profitable new production platforms for lower CAPEX & OPEX
The rising demand for high-quality recombinant therapeutics has driven development of cell–based manufacturing systems for improved production yields. Protein therapies now treat a vast number of indications including cancer, diabetes, and inflammatory diseases, and provide a rapid response vaccine platform. Monoclonal antibodies represent the largest market segment at 40% of global market.
Other categories include vaccines, antibody-drug conjugates, enzyme replacement, diabetes treatments including recombinant insulin, interferons and blood factors Global market for drugs is predicted at $248.7 Bn this year (pre-Covid calculations).
In terms of total revenue from biologics, monoclonal antibodies represent the largest market segment. The increased incidence of many chronic diseases has driven use of monoclonal antibodies. Vaccines are another growth segment in the biopharmaceutical industry. The improving economic conditions (pre-Covid 19), increasing public awareness of vaccination, and global efforts of governments to eradicate viral and bacterial infections are key drivers.